OUR MISSION
Biologics discovery needs more than generic AI
AI-guided design holds enormous promise for accelerating development pipelines. However, most models are not designed to address the developability, manufacturability, or stability issues behind most drug candidate failures.
Built by the scientists behind 20+ FDA-approved therapies, EMLy Co-pilot addresses this gap.
Compress discovery from weeks to minute
EMLy helps you move faster by orchestrating models, datasets, and computational resources so you can focus on your science.
Turn conversation into actionable science
Through a simple yet scientifically fluent chat interface, EMLy transforms your questions into high-impact, design-ready outputs.
Built to adapt to real therapeutic challenges
Grounded in rich immunological data and experimental validation, EMLy can help you explore multiple modalities (mAbs, TCRs, and more!)
OUR PLATFORM
EMLy Co-pilot: one interface, many capabilities.
EMLy Co-pilot is an integrated AI platform that unifies biologics design workflows, previously requiring dozens of bioinformatics and computational tools, into a single, conversational experience.
The Co-pilot experience
Go from conversation to candidate in minutes
Your time is valuable. Spend it on the science that counts, while the co-pilot tackles the tedious, manual work:
-
Finding and manipulating structural models
-
Creating and evaluating variants
-
Designing candidate libraries
-
Streamlining cloning workflows
Underpinned by powerful, validated computational capabilities
Proprietary
structural modeling
Evaluate structural elements associated with therapeutic function and efficacy
Variant
generation
Enables iterative thinking and design branching to produce variants in minutes
Biologics
optimization
Engineers molecules for improved stability, expression, and manufacturability
Machine learning
model development
Scans through immune datasets to learn the ‘language’ of effective immune motifs
OUR MISSION
Pioneer the combination of machine and human intelligence to develop the best immunotherapies for cancer patients in urgent need
3
TCR and Antibody specific LLMs fine-tuned/created
3
Pipeline programmes
6
In silico design to lead candidates in six months
HOW CAN WE HELP YOU?
Elevate your drug discovery outcomes.
We deliver safer, more precise drug candidates for your pipeline – faster.
How it works
Rapid design & engineering of new candidates and biobetters
Design, optimise and validate TCRs, Antibodies, Bispecifics and VHHs.
See how we engineered a TCR to 5 million fold improvement using our EMLy AI.
See how we supercharge stability and developability of a TCR asset.
Unlock the full potential of your research with EMLy Co-pilot & LLMs
Industry-first TCR and antibody-specific LLMs connected to EMLy co-pilot, empowering scientists with cutting-edge informatics & insights.
Discover how we identify novel targets and therapeutics through the Long term Cancer Survivor Program
Leverage our unmatched scale in deep sequencing, enhanced by EMLy AI error correction, to boost immune repertoire accuracy and align with our exclusive proprietary databases.
Discover how we identify our next target through the Long Term Survivor Programme.
OUR TECHNOLOGY
Introducing EMLy™
The world’s leading repertoire decoding technology specifically built for TCR, Antibodies & Bi-Specifics.
A multi-modality platform
EMLy’s protein language models are designed to be both modality- and disease-agnostic. As solution architects, we recognise that there is no one-size-fits-all approach to protein design—each solution is uniquely tailored to meet specific therapeutic needs.
TCR
Antibody
Bispecific
VHH
OUR STUDY
The Long-term Cancer Survivor Study
Samples
We can access blood and tumour samples, directly or via University of Surrey.
Sequencing
We can deep sequence immune sequence immune repertoires and have databases of 1bn TCRs and 2bn antibodies.
Analysis
We can analyse repertoires with our proprietary LLMs.
Engineering
We can engineer TCRs & antibodies into immune engagers.
INTRODUCING CO-PILOT
Your partner in AI driven drug discovery
OUR PARTNERS
ETCEMBLY PROGRAMS
OUR CASE STUDIES
At the forefront of innovation
1
Affinity optimisation
2
Stability and developability
Affinity optimisation
EMLy™ can take TCR/
antibody sequences
and predict affinity
matured variants
Protocol driven molecular docking
...to explore the
complex conformational phase space
High throughput screen of protein variants
Evaluation of
dynamic interactions
Top 50 hit candidate variants selected for validation testing
stability and developability
With EMLy you can
supercharge stability
and developability
of your asset
Combining alpha
& beta mutations results in a 20-fold increased expression yield
OUR MOTIVATION
For teams building the next generation of biologics
From nimble seed-stage biotechs to global R&D organizations, EMLy gives scientists access to advanced AI-driven biologics discovery, without requiring specialized computational expertise.
Preclinical
Lead
optimization
& CMC
Hit-to-lead
Target -to-hit
Target hypothesis
Custom workflow:
Proprietry immune sequencing.
Co-pilot
Custom workflow:
Immune repertoire analysis.
Small molecule design.
Co-complex prediction.
Custom workflow:
Antibody expression enhancement.
OUR TEAM
Developed by scientists
Our technology is built by our scientists, who are behind 20+ FDA-approved therapies. We are committed to developing the next generation of scientists and welcome motivated individuals who share our vision. If you aspire to break boundaries in precision medicine and are able to demonstrate understanding in the convergence of these fields, we are interested in hearing from you.
Michelle Teng
CEO
Co-founder
20 years of experience across pipeline from discovery to translational medicine in Immunocore (KIMMTRAK) & AstraZeneca (FluMist)
Jacob Hurst
CTO
Co-founder
25 years of experience in translational medicine (KIMMTRAK), TCR and antibody repertoire analytics (Abysis)
NICK PUMPHREY
CSO
Over 20 years of experience developing TCR-based therapeutics at Immunocore and Adaptimmune (Afamicel)
MITHI THAYA
Tech Advisor
Experienced tech
founder with multiple
successful exits
JOHN MCCAFFERTY
Scientific Advisor
Serial entrepreneur.
Founder of Cambridge
Antibody Technology,
Maxion Tx, IonTas
NICK CROSS
Chairman
Serial founder and investor
with considerable Board
experience, including
Immunocore,
Adaptimmune, Oxford
Asymmetry and Oxford
Semiconductor Ltd
Bent Jakobsen
Director
TCR therapies pioneer.
Founded Immunocore
and Adaptimmune
< SWIPE TO SEE MORE >
